Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA.
E FelipB C ChoV GutiérrezA AlipB BesseS LuA I SpiraN GirardR CalifanoS M GadgeelJ C-H YangS YamamotoK AzumaY J KimK-H LeeP DanchaivijitrC G FerreiraY ChengM A N SendurG-C ChangC-C WangK PrabhashY ShinnoD StroyakovskiyL Paz-AresJ R Rodriguez-CidC MartinM R G CampeloH HayashiD NguyenP TomasiniM GottfriedC DoomsA PassaroM SchulerA C Z GelattiS OwenK PerdrizetS-H I OuJ C CurtinJ ZhangM GormleyT SunA PanchalM EnnisE FennemaM DakshS SethiJ M BaumlS-H LeePublished in: Annals of oncology : official journal of the European Society for Medical Oncology (2024)
Amivantamab-lazertinib effectively overcomes the effect of high-risk features and represents a promising new standard of care for patients with EGFR-mutant advanced NSCLC.